The present invention relates to high dose oral pharmaceutical compositions of artemether and lumefantrine, and process for preparation thereof. The compositions comprise of artemether and lumefantrine comprising artemether in an amount of from about 40 mg to about 80 mg, lumefantrine in an amount of from about 240 ...

A once-a-day bioequivalent sustained release formulation of diltiazem comprising blend of delayed release and fast release pellets of diltiazem in a unit dose containment system and process of preparation thereof is disclosed.

The present invention relates to an in-situ gel forming injectable depot liquid composition of Olanzapine, the composition comprising: a) Olanzapine; b) a biocompatible, biodegradable polymer; and c) a biocompatible organic solvent, wherein the biocompatible, biodegradable polymer and the organic solvent are present...

The present invention relates to Form I of duloxetine hydrochloride and its preparation.

The present invention provides a novel process for the preparation of pure Valganciclovir hydrochloride.

A label comprising an inbuilt hanger for pharmaceutical products particularly intravenous feeding bottle is disclosed. The inbuilt hanger is peeled apart from the remaining portion of the label and is used for suspending the bottle from a conventional intravenous feeding stand.

The present invention relates to a meter for the calculation of Urticaria Activity Score (UAS) on the basis of EAACI/GA2LEN/EDF/WAO guidelines. The meter displays the wheal score and the pruritis/itch score which are then instantly added to calculate the Urticaria Activity Score (UAS).

The present invention relates to a pharmaceutical composition of olopatadine suitable for nasal administration and processes for the preparation of the same.

Modified release pharmaceutical compositions of cephalexin and clavulanate and process of preparation thereof is disclosed. Cefalexin is present in the modified release segment and clavulanate in the immediate release segment.

Provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists ("MRA"), and at least one additional active ingredients selected from one or more p2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceu...

The present invention relates to stable pharmaceutical compositions comprising nateglinide of Form B and processes for making them which include a step of pulverization.

The present invention relates to a process for the preparation of taste masked dosage forms.

The present invention provides a novel polymorphic form of memantine hydrochloride. The novel polymorphic form has been designated as Form R of memantine hydrochloride. The invention further provides a process for preparation of this polymorphic form. In addition the invention provides pharmaceutical compositions co...

The present invention relates to substituted aromatic compounds, which have peroxisome proliferation activated receptor (PPAR) modulating activity, and hence can be used as anti-diabetic agents. Process for the preparation of compounds disclosed herein, pharmaceutical compositions thereof, and the methods for treati...

The present invention provides a process for the preparation of Doripenem.

The technical field of the present invention relates to stable aqueous solution of risperidone for oral administration and process for preparation thereof.

The present invention relates to magnesium salts of HMG-CoA reductase inhibitors, processes for their preparation, pharmaceutical compositions thereof and methods of using compositions to treat mammals suffering from hypercholesterolemia.

A process for the synthesis of new triazole compounds as therapeutic agents for fungal infections having improved antifungal activity as compared with bluconazole and itraconazole.

The present invention provides a process for the preparation of Meropenem.

The present invention relates to a process for the preparation of 6-(5-chloropyridin-2- yl)-5H-pyrrolo[3,4-b]pyrazine-5,7(6H)-dione of Formula I. The present invention further relates to a process for the preparation of eszopiclone using 6-(5-chloropyridin-2-yl)-5H-pyrrolo[3,4-b)]pyrazine-5,7(6H)-dione of Formula ...

The present invention relates to hydrobromide salt of donepezil, its polymorphic forms I and II, processes for preparing them, pharmaceutical compositions of the salt and methods of treatment to comprising administration of the salt.

This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, inc...

A compound of Formula III Wherein R1 is hydrogen or lower alkyl; A is phenyl or heteroaryl selected from the group comprising of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and oxazolyl; n is an integer having a value between 0 to 5; B is hydrogen, -COOH or pharmaceutically acceptable sa...

The application relates to the process for the preparation of novel amorphous form of losartan potassium which comprises dissolving crystalline losartan potassium in suitable solvent(s) water or mixture thereof and recovering losartan potassium in the amorphous form.

The present invention relates to novel polymorphic form of efavirenz. The novel polymorphic form is designated as Form y2 of efavirenz.

The present invention provides processes for the preparation of amorphous form of sitagliptin dihydrogen phosphate. It also provides a solid dispersion of sitagliptin dihydrogen phosphate including in the amorphous form and processes for its preparation.

The present invention relates to a novel polymorphic form of duloxetine hydrochloride and its preparation. The novel polymorphic form is designated as Form I of duloxetine hydrochloride. The present invention further relates to duloxetine hydrochloride having enantiomeric purity of about 98% or above. The present in...

The present invention relates to a process for the purification of nucleoside analogues which does not employ chromatographic techniques.

The present invention provides a process for the preparation of (-) pramipexole or an acid addition salt thereof of Formula I The present invention further provides polymorphic Forms A and B of anhydrous pramipexole dihydrochloride.

The present invention relates to pharmaceutical composition of atovaquone comprising at least 15% of the particles greater than 3 um.

Stable pharmaceutical compositions of ACE inhibitors using low amount of magnesium carbonate as the stabilizing are disclosed. Further, a process for their preparation is also disclosed.

The present invention relates to a process for the preparation of eszopiclone.

The present invention relates to novel polymorphic form of pregabalin and process for its preparation. The novel polymorphic form of pregabalin has been designated as Form I of pregabalin. The present invention further provides enantiomerically pure pregabalin or salt thereof having less than 0.03%w/w of unwanted (R...

The present invention provides novel polymorphic forms of (R)-(-)-Tamsulosin, process for their preparation and pharmaceutical compositions thereof. The invention further provides a process for preparation of these polymorphic forms.

The present invention relates to an extended release pharmaceutical composition comprising valproic acid, a phar-maceutically acceptable salt, ester, or amide thereof or divalproex sodium.

The present invention relates to a process for the preparation of diastereomerically and enantiomerically pure oxetan-2-ones. The present invention also relates to a process for the preparation of ester derivatives of oxetan-2-ones. The present invention further relates to compounds prepared by such processes. ...

A process for the preparation of a compound of Formula I, as shown in the accompanied drawings, wherein R is cyano, phenyl, cyclohexadienyl, heterocyclyl, heterocyclylthio, or a heterocyclylamido group, wherein the phenyl or the heterocyclic ring may be further substituted by an alkyl, ...

The present invention relates to certain carbocyclic or heterocyclic derivatives as caspase inhibitors and to the processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as caspase inhibitors. The compounds of this inventio...

A solid, particulate composition formed by the inter-polymer complexation of a cationic polymeric glucosamine or its derivatives and an anionic, cross-linked, polyacrylic acid or its derivatives. This complex is particularly useful in oral solid pharmaceutical compositions, including tablets and capsules. ...

A solid dosage form comprising valsartan and amlodipine, wherein the active agents are present in an amount of less than 35% by weight based on the total weight of the solid dosage form; and process of preparation thereof is disclosed.

The technical field of the present invention pertains to controlled release pharmaceutical composition of tolterodine and processes for the preparation of multiple unit pharmaceutical composition of tolterodine. The controlled release pharmaceutical composition of tolterodine includes one or more coated units. Each ...

The technical field of the invention relates to ibuprofen-containing soft gelatin capsules, pharmaceutical compositions of a substantially clear ibuprofen solution, and process for their manufacture. It also relates to pharmaceutical compositions of substantially clear solutions containing ibuprofen and pseudoephedr...

The present invention relates to enteric coated didanosine compositions having a subcoat comprising hydroxypropyl methylcellulose, and process for preparation thereof. The enteric coating ranges from 19-25% w/w of the composition. The compositions are stable and have acceptable acid resistance and release profile. ...

Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for tre...

The present invention relates to an improved and industrially advantageous process for the preparation of citalopram and pharmaceutically acceptable acid addition salt thereof.

The present invention relates to an oral solid dosage form that includes a combination of a biguanide and a sulfonylurea wherein the dosage form provides an extended - release phase of the biguanide and an immediate-release coating containing the sulfonylurea. Also provided a process for the preparation of the oral ...

The present invention relates of an improved process for selective methylation of a hydroxy group at the 6-position of an erythromycin A derivative which comprises methylating the erythromycin A derivative with a methylating agent in a solvent system containing polar aprotic solvent and toluene at a ratio from 1:1 t...

Controlled-release metformin and processes for their preparation, using a combination of non-ionic and anionic hydrophilic polymers, wherein the total hydrophilic polymer concentration is at least about 16% by weight of the composition.

The present invention provides a process for the purification of citalopram or its acid addition salt thereof.

The present invention relates a process of preparation of stable pharmaceutical composition comprising Nateglinide Form B wherein the process comprises a step of pulverization.

The present invention is directed to a pharmaceutical composition exhibiting enhanced dissolution and bioavailability of cefpodoxime proxetil which is attained through adsorption of the micronized drug on to a pharmaceutical carrier to form cefpodoxime - carrier adsorbates.

A process for the preparation of fast dissolving / disintegrating tablets where the porosity is produced by in-situ gas generation through moisture activation of the effervescent mixture comprising acid and a base in a tablet by exposing tablet to controlled humidity in a relative humidity chamber at a temperature o...

The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity.

The present invention relates to a process of preparing a stable pharmaceutical composition of pravastatin or its pharmaceutically acceptable salts which is achieved by mixing pravastatin with suitable amounts of carrier, i.e., diluent, lubricant and, optionally other pharmaceutically accepted excipients and then co...

A stable pharmaceutical composition of paroxetine, comprising (a) paroxetine, (b) microcrystalline cellulose, and (c) one or more pharmaceutically acceptable inert excipients selected from the group consisting of fillers, binders, disintegrants, wetting agents, stabilizers, lubricants/glidants, flavouring agent...

The present invention relates to an improved process for the preparation of trifluoromethanesulfonic ester of ethyl (R)-2-hydroxy-4-phenylbutyrate, useful as intermediate for the preparation of ACE (Angiotensin Converting Enzyme) inhibitor, benazepril.

The present invention relates to novel polymorphic form of efavirenz. The novel polymorphic form is designated as Form yl of efavirenz.

The present invention relates to a process for the preparation of 6-(5- chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-6]pyrazin-5-one of Formula I. (FORMULA REMOVED) The present invention further relates to a process for the preparation of eszopiclone using 6-(5-chloropyridin-2-yl)-7-hydrox...

The present invention relates to an improved process for the preparation of angiotensin converting enzyme (ACE) inhibitor, fosinopril sodium.

A method of reducing fat absorption in mammals includes orally administering to the mammals an effective amount of an inter-polymer complex formed between a polymeric glucosamine or its derivative and a polyacrylic acid or its derivative. The inter-polymeric composition can be in the form of a pharmaceutical composi...

The present invention relates to stable solid dosage form and a dry process for the preparation of amorphous Cefditoren pivoxil solid dosage forms and coating the dosage form with one or more layers of aqueous dispersion of film forming agents.

The present invention relates to a new and industrially advantageous one-pot process for the preparation of alkyl 3-cyclopropyl amino-2-[2,4-dibromo-3-(difluoromethoxy)benzoyl]-2-propenoate, which are valuable intermediates for the production of highly active antibacterial quinolone medicaments. ...

A pharmaceutical composition comprising sertraline or a pharmaceuticaliy acceptable salt thereof and water and one or more non-aqueous vehicles, preservatives and flavouring agents, wherein the water comprises greater than about 10% w/w to about 40% w/w of the composition.

The present invention relates to pulsatile release dosage forms of losartan, wherein said dosage forms provide pulsatile release of losartan after a predetermined lag time. It also relates to processes for the preparation of said pulsatile release dosage forms.

The invention relates to a process of preparing an extract of stem of Premna integrifolia Linn and further extracting a compound of Formula I. The compound extracted from the plant Premna integrifolia Linn is useful for the treatment of inflammatory conditions such as AIDS, asthma, arthritis, bronchitis, chronic obs...

The present invention relates to an improved process for the preparation of pure levetiracetam, with good yield and purity is provided.

This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of discl...

The present invention relates to stable parenteral formulations of tigecycline and process of preparation thereof, wherein the formulation comprises of an edetate, a pH modifying agent or an antioxidant, such that the formulation remains stable for at least for 45 hours.

A method of drying nelfinavir mesylate, wherein the said method comprises, a) feeding a solution or a slurry of nelfinavir mesylate into an agitated thin film dryer (ATFD), b) drying the fed nelfinavir mesylate by agitated thin film drying, and c) collecting dry nelfinavir mesylate from the agitated thin film d...

The present invention provides a method for identifying a compound as selective inhibitor of PDE10 subtype employing luciferase based reporter gene assay. The method of the present invention provide a simple and sensitive assay for high throughput screening of compounds as selective inhibitor of PDE10 subtype for de...

The present invention provides sitagliptin 4 methylsalicylate sitagliptin myristate sitagliptin isophthalate sitagliptin isonicotinide sitagliptin adipate their polymorphic form processes for their preparation and pharmaceutical compositions thereof.

The present invention discloses an improved and cost effective process for purification and isolation of pharmaceutical grade cefpodoxime proxetil.

The invention relates to process for preparing a parenteral composition of ondansetron hydrochloride, the process comprising the steps of a) adding ondansetron hydrochloride into an aqueous solvent comprising one or more hydroxy acids to obtain a clear solution, b) adding one or more bases and optionally one or more...

The present invention relates to isoxazoline derivatives and their analogues, which can be used as phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibito...

The present invention relates to a process for the direct preparation of malic acid salt of sunitinib.

The present invention relates to a process for the preparation of duloxetine, its intermediates and salts thereof.

The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates.

A method for preparation of controlled release multiple unit system of glipizide is disclosed. Individual units comprising glipizide are coated with controlled release layer and optionally with inert and non functional waxy layers.

The present invention relates to a cost effective and commercially viable process for the preparation of cefpodoxime acid at an industrial scale.

The present invention relates to mouth dissolving tablets comprising olopatadine and the process of preparation of the same.

The present invention relates to a process for the isolation of pure crystalline imipenem monohydrate.

abc

The present invention relates to process for the preparation of crystalline N-formimidoyI thienamycin monohydrate in the presence of a secondary amine in a suitable N-substituted lactam or N, N-disubstituted amide.

The present invention relates to simple and cost-effective processes for the preparation of ether derivatives of dihydroartemisinin. The present invention further enables preparation of pure B-ether derivatives of dihydroartemisinin which are well-known antimalarial agents.

A sugar-free nutraceutical composition, having improved taste and texture comprising one or more non-sugar sweeteners, and one or more texture forming agents is disclosed. Further process of preparation thereof is also disclosed.

abc

The present invention relates to a pharmaceutical composition for topical delivery comprising a pharmaceutically effective amount of drug(s) that acts as a cyclooxygenase-2 enzyme inhibitor. The composition provides better percutaneous absorption and enhanced efficiency.

The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity.

The present invention relates to controlled-release tablets of metformin and processes for their preparation, wherein the tablets comprise 16% by weight of the composition of hydrophilic polymers consisting of anionic and nonionic polymers in a ratio 1:1 to 1:5. The anionic polymer is sodium carboxymethylcellulose a...

The present invention provides a novel process for the preparation of 10 oxo 10 11 dihydro 5 dibenzo[]azepine 5 carboxamide commonly known as oxcarbazepine which is a medicament and a useful intermediate in the preparation of eslicarbazepine acetate. The present invention further provides a process for the preparati...

The present invention provides a process for the preparation of asenapine maleate of Formula (I) comprising: intra molecular cyclization of the intermediate of Formula (II) to obtain the intermediate of Formula (III) using aluminium halide.

The present invention relates to orally disintegrating compositions comprising angiotensin II receptor antagonists. It also relates to orally disintegrating compositions comprising combination of angiotensin II receptor antagonists and other antihypertensive drugs. It further relates to processes for preparing such ...

Provided herein is a process for the preparation of crystalline Form G of febuxostat in which the crystalline Form G of febuxostat is formed from a mixed solvent of methanol and water having a volume ratio of methanol to water of from 5:95 to 45:55.

The present invention relates to pharmaceutical dosage forms comprising; (i) immediate release unit of carbidopa and levodopa; (ii) an extended release unit of carbidopa and levodopa; and (iii) an immediate or extended release unit of salt of carboxylic acid.

The present invention relates to a crystalline form of fosamprenavir calcium. The crystalline form of the present invention is designated as Form II of fosamprenavir calcium. The present invention also relates to a process for the preparation of crystalline Form II of fosamprenavir calcium. The present invention fur...

The present invention provides a stable cefozopran composition for parenteral administration comprising of cefozopran, isotonic agent and an alkali metal salt wherein the composition is prepared by aqueous based lyophilization.

The present invention provides a modified release pharmaceutical formulation of amoxicillin and the method of preparation thereof. The pharmaceutical formulation is in the form of a bilayer tablet of amoxicillin comprising (a) an immediate release portion comprising amoxicillin and one or more pharmaceutically accep...

The present invention provides hydrobromide salt of dabigatran etexilate of formula (IV) and its process for the preparation. The present invention further provides crystalline Form I and crystalline Form II of hydrobromide salt of dabigatran etexilate and processes for their preparation. The present invention furth...

The present invention relates to timed extended-release pharmaceutical compositions comprising metoprolol and an extended-release polymer. The pharmaceutical compositions of the present invention exhibit a lag time of at least 2 hours and provide an extended-release of metoprolol for at least 20 hours. ...

The present invention relates to the N Methylformamide solvate of dasatinib a process for its preparation. Formula (I)

The invention provides an alternative extended release dosage form of trospium or its pharmaceutically acceptable salts and methods of preparation thereof. The dosage form of the present invention is bioequivalent to the innovator"s product Sanctura® XR.

An improved and efficient process for the preparation of 2 [3 cyano 4 (2 methylpropoxy)phenyl] 4 methylthiazole 5 carboxylic acid (febuxostat) that is substantially free from amide by product is provided.

The present invention relates to stable dispersible formulation of arterolane maleate and piperaquine, wherein the formulation exhibits enhanced structural integrity and is able to disperse in water within 3 minutes. The dispersible formulation presents acceptable taste and leaves minimum residue in the mouth. Th...

The present invention provides a stabilized controlled release pharmaceutical composition comprising Gliclazide and sodium citrate as stabilizing agent; and process for the preparation of said pharmaceutical composition.

The present invention provides a stable lyophilized cefozopran composition for parenteral administration prepared by a lyophilization process and wherein the solvent system used in lyophilization process comprises an aqueous solvent and at least two organic co-solvents.

The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts.

The present invention relates to a polymorphic form of olmesartan medoxomil and a process for the preparation of crystalline olmesartan medoxomil.

The present invention relates to a non-aqueous topical composition comprising a therapeutically effective amount of aceclofenac, a gelling agent and a non-aqueous solvent. It further relates to the process for the preparation thereof.

The present invention relates to amorphous vilazodone hydrochloride, its process of preparation and pharmaceutical composition thereof

PROCESS FOR THE PREPARATION OF CARBAPENEM COMPOUNDS The present invention relates to a process for the preparation of carbapenem compound of Formula I. wherein P1 is hydrogen or a carboxyl protecting group, P3 is hydrogen or a hydroxyl protecting group, R1 is C1-3 alkyl, and A is selected from a group consisti...

The present invention relates to an osmotic floating tablet comprising: (i) an inner core comprising a drug one or more low density polymers and one or more pharmaceutically acceptable excipients; and (ii) an outer osmotic coating surrounding the inner core that is substantially permeable to surrounding fluids and s...

This invention relates to a pharmaceutical composition comprising a combination of phentennine in an immediate release form and topiramate in an extended release form. Further, it relates to processes for the preparation of the composition and the method of using the composition.

This invention also relates to pharmacological compositions containing the compounds of the present invention and methods of treating asthma rheumatoid arthritis COPD rhinitis osteoarthritis psoriatic arthritis psoriasis pulmonary fibrosis pulmonary inflammation acute respiratory distress syndrome perodontitis multi...

The present invention relates to certain sulfone acetic acid derivatives of formula I as MMP inhibitor and processes for its syntheses. The invention also relates to pharmacological compositions containing the compounds of the present invention and methods of treating asthma rheumatoid arthritis COPD rhinitis osteoa...

The present invention relates to process for the preparation of fosamprenavir calcium.

The present invention relates to process for the preparation of lenalidomide.

The present invention relates to an in-situ process for the preparation of polymorphic Form A of lenalidomide.

The present invention provides stable amorphous tigecycline, a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of i complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. ...

The invention relates to a stable aerosol composition comprising a combination of Ciclesonide and one or more other active ingredients.

The present invention provides a process for the preparation of sorafenib tosylate.

The present invention provides a process for the preparation of pazopanib of Formula Ia or salts and intermediates thereof.

The present invention provides compounds of Formula III and Formula VI and processes for their preparation. The present invention further provides use of the compounds of Formula III and Formula VI for the preparation of tofacitinib or isomers or a mixture of isomers or salts thereof.

The present invention relates to stable pharmaceutical compositions comprising rifaximin and processes for their preparation.

A controlled release pharmaceutical dosage forms of trimetazidine and the process of preparation thereof, suitable for once-daily dosing is disclosed. The controlled release pharmaceutical dosage form of trimetazidine comprises trimetazidine or its pharmaceutically acceptable salts; one or more gel-forming materials...

The present invention relates to a process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof.

The present invention relates to a gastroretentive tablet comprising pregabalin, an acrylic acid polymer, one or more swellable polymers, and other pharmaceutically acceptable excipients. It further relates to a process for the preparation of same.

The present invention relates to a process for the preparation of pure meropenem trihydrate.

The present invention provides sorafenib ethane sulphonate, process for its preparation, pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer.

The invention relates to a delayed release pharmaceutical composition of mesalamine comprising: a) granules comprising mesalamine or pharmaceutically acceptable salts thereof and a hydrophilic polymer; b) extragranular excipients; wherein the pharmaceutical composition is further coated with a single layer of polyme...

The present invention relates to extended release pharmaceutical compositions of paliperidone and process of preparation thereof.

The present invention relates to processes for the preparation of dasatinib and its intermediates.

The present invention relates to a stable oral pharmaceutical dosage form comprising imatinib mesylate and one or more pharmaceutically acceptable excipients wherein the amount of imatinib calculated as free base is more than 80% by weight based on the total weight of the oral pharmaceutical dosage form, and wher...

A tamper evident kit packaging system for injectable products wherein the kit package is formed of a top panel, a bottom panel, a spine panel, a front closing panel and two side closing panels to form a box type kit pack, wherein the said box type kit pack comprises of one or more independent compartments on the inn...

The present invention relates to a process for the preparation of substituted 1,3-oxathiolanes. The present invention specifically relates to a process for the preparation of lamivudine.

The present invention relates to process and intermediates for the preparation of substituted 1,3-oxathiolanes. The present invention specifically relates to a process for the preparation of lamivudine.

The present invention relates to a stable crystalline Form I of lamivudine. The present invention further relates to a process for the preparation of the stable crystalline Form I of the stable crystalline Form I of lamivudine.

The present invention relates to stable crystalline Form II of L malic acid salt of sunitinib and its preparation.

The present invention relates to controlled-release pharmaceutical compositions comprising budesonide or pharmaceutically acceptable salts thereof and a matrix consisting essentially of hydrophobic and hydrophilic release-controlling agents. It further relates to processes for the preparation of said pharmaceutical ...

The field of the invention relates to pharmaceutical composition of c/s-adamantane-2-spiro-3,-8"-[[[(2"-amino-2"-methylpropyl)amino]carbonyl]- methyl] -1",2",4"-trioxaspiro[4.5]decane, in combination with piperaquine, and processes for their preparation.

The present invention provides processes for the preparation of rivaroxaban and its intermediates.

The present invention relates to a closure assembly comprising a metered dosing system which is installed upon a liquid drug formulation container to normally maintain the mouth of such a container closed during periods of non-use, but which, when opened, is operable to dispense the specified amount of said liqui...

The present invention relates to a topical applicator comprising (i) a tube containing a semi-solid dosage form; and (ii) a massaging assembly.

PULSATILE RELEASE PHARMACEUTICAL FORMULATION OF DEXLANSOPRAZOLE The present invention relates to a pulsatile-release pharmaceutical formulation of dexlansoprazole composed of a single type of enteric coated pellets and the process for the preparation thereof.

The present invention relates to a process for the production of a molded dosage form comprising a drug and a pharmaceutically acceptable excipient. The said process is capable of producing molded dosage form on an efficient continuous system and can be used for production of both immediate release and extended rele...

The field of the invention relates to pharmaceutical composition of cis-adamantane-2-spiro-3"-8"-[[[(2"-amino-2"-methylpropyl)amino]carbonyl]- methyl] -1",2",4"-trioxaspiro[4.5]decane, in combination with piperaquine, and processes for their preparation.

The present invention provides an improved process for stereoselective preparation of 5 fluoro l (2R 5S) [2 (hydroxymethyl) l 3 oxathiolan 5 yl]cytosine and pharmaceutically acceptable salts thereof.

The present invention relates to a process for the preparation of bortezomib (Formula I) and its intermediates.

The present invention relates to a process of preparation of malic acid salt of sunitinib.(I).

The present invention relates to crystalline forms of dexlansoprazole designated as forms A and B and their preparation. The present invention further relates to processes for the preparation of anhydrous dexlansoprazole and dexlansoprazole sesquihydrate using crystalline Forms A and B of dexlansoprazole. ...

The present invention provides crystalline Form R of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, process for its preparation, pharmaceutical composition comprising it and its use for the chronic management of hyperuricemia in patients with gout.

The present invention provides a new polymorphic form of rifaximin designated as DMF solvate and the process for its preparation. It also provides a pharmaceutical composition comprising the same and its use for the treatment of bowel related disorders.

The present invention relates to a process for the preparation of crystalline dexlansoprazole.

The present invention relates to an improved process for the preparation of quetiapine and pharmaceutically acceptable salts. It also relates to improved process for the preparation of intermediates of quetiapine.

The present invention relates to the salts of dexlansoprazole in amorphous form. The present invention further relates to processes for the preparation of salts of dexlansoprazole.

The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a novelCrystalline form of erlotinib trifluoroace...

The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro- 3-(trifluoromethyl)phenyl]ureido }phenoxy)-N 2 -methylpyridine-2-carboxamide, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel H...

The present invention relates to processes for reducing impurities in lacosamide during the preparation of lacosamide. The invention provides processes for minimizing or removing impurities such as (2R) 2 (acetylamino) 3 (benzylamino) 3 oxopropyl acetate of Formula II or (2R) 2 propanoylamino N benzyl 3 methoxypropi...

The present invention provides a process for the preparation of ceftaroline fosamil and its intermediates. The present invention also provides a process for the preparation of ceftaroline fosamil propionate monohydrate and ceftaroline fosamil acetate monohydrate.

The present invention provides a process for the preparation of desloratadine.

The present invention relates to a reclosable folding carton for packaging of pharmaceutical dosage forms with a built-in tamper-evident feature.

This invention relates to an improved process for the preparation of compounds of Formula I, salts of the free base cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-methyl propyl) amino] carbonyl] methyl]-1', 2', 4'-trioxaspiro [4.5] decane, Formula I wherein X is an anion. The compounds of Formula I have antimalarial ...

The present invention provides polymorphic form R of desvenlafaxine succinate and the process for its preparation. It also provides a pharmaceutical composition comprising the same and its use for the treatment of major depressive disorder (MDD).

The present invention relates to a process for the preparation of dexlansoprazole.xHiO, wherein x is about 0.0 to about 0.1, using dexlansoprazole.xH 20 , wherein x is about 2.6 to about 50.

The present invention relates to orally disintegrating ondansetron formulations and process of making thereof. The orally disintegrating ondansetron formulation comprises: a) ondansetron particles having a D90 of not more than 30 microns; b) ondansetron particles having a Dgo ranging from 90-200 microns; c) one or m...

The present invention relates to solid dosage forms for oral administration of an azabicyclo derivative or it’s pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs and metabolites; and processes for the preparation of such solid dosage forms. The solid dosage forms can be c...

A process for the preparation of pharmaceutical composition of azole antifungal compound comprising multiple drug loaded core units is disclosed. In particular, a process wherein the bed temperature is from 20° C to 35° C, and inlet air relative humidity is from 35 % to 55 % is disclosed.

The invention relates to fixed dose combinations of sumatriptan and a non-steroidal antiinflammatory drug (NSAID), like naproxen. It relates to bilayer tablets comprising sumatriptan and naproxen, and process of preparation thereof.

Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary or gastrointestinal system mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions comprising compounds described...

This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepr...

The invention provides polymorphic forms of the HMG-CoA reductase inhibitor (3R, 5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4- hydroxymethylphenylamino)carbonyl] -pyrrol- 1 -yl]-3,5-dihydroxy-heptanoic acid, hemi calcium salt. The invention also provides methods for preparing these polymorphic forms, pharma...

The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphy...

The invention relates to processes for the preparation of pure galantamine or pharmaceutically acceptable salts thereof. More particularly, it relates to the preparation of pure galantamine hydrobromide. The invention also relates to pharmaceutical compositions that include the pure galantamine or pharmaceutically a...

The present invention relates to heterocyclic derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock...

The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against bacterium such as Staphyloc...

The present invention relates to a multiparticulate extended-release pharmaceutical composition of mesalamine, comprising a) an inert core, b) an active ingredient layer and one or more phannaceutically acceptable excipients, c) an inner coating layer comprising a water- insoluble cellulose derivative, and ...

The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions.

The present invention relates to improved processes for preparing intermediates of valsartan or its salts.

The present invention relates to controlled release oral dosage forms of galantamine or acceptable salts thereof and processes for the preparation thereof.

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I di...

Processes for preparing pure tiagabine, a piperidine carboxylic acid, using pharmaceutically acceptable acid addition salts of tiagabine esters are provided. L (+)-tartaric acid, oxalic acid and dibenzoyl L (+)-tartaric acid addition salts of tiagabine esters are also provided. Further, processes for preparing acid ...

Extended release pharmaceutical composition of paliperidone and process of preparation thereof is disclosed.

A pharmaceutical dosage form comprising citalopram, wherein not less than about 36% of the citalopram particles, by volume, have a particle size that is less than about 5 µm.

A barium salt of the S-enantiomer of omeprazole which is (S)-5-methoxy-2-[[(4- methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-lH-benzimidazole is provided. Further, processes for preparing the barium salt, pharmaceutical compositions comprising the salt and a method of treatment or prevention of gastrointestin...

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. P...

A stable oral composition of azithromycin comprising: an azithromycin premix comprising azithromycin monohydrate and at least one additive; at least one pharmaceutically accepted excipient; and optionally, at least one taste masking agent.

This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of discl...

An extended release pharmaceutical composition comprising: a) a drug capable of dissociating to produce a valproate ion; and b) at least one extended release polymer; wherein the pharmaceutical composition is manufactured under controlled atmospheric conditions.

The present invention relates to solid oral dosage forms containing ziprasidone and salts thereof having reproducible dissolution profiles and process for the preparation thereof.

The present invention relates to a novel quaternary ammonium salt useful as a potential intermediate in the preparation of amoroline and its salt.

A sweetener tablet of stevia extract prepared by driect compression method is disclosed.

The present invention relates to pharmaceutical composition for oral administration comprising sertraline or pharmaceutically acceptable salts thereof, having a particle size of d90 ranging from about 20 um to about 40 um and d50 ranging from about 5 um to about 15 um, wherein the comosition is bioequivalent to a re...

The invention relates to novel modified release multiple unit systems, and methods of preparing these systems, which can be easily compressed into tablets or filled into capsules or sachets without affecting the desired release characteristics of the pharmaceutical active ingredients incorporated within the systems....

The present invention relates to an oral solution of galanthamine comprising galanthamine or a pharmaceutically acceptable acid addition salt thereof and 4% to 10% w/v of one or more polyols; wherein the composition is free from intense sweeteners and has acceptable organoleptic properties.

The present invention relates to a solid dosage form for the combination of biguanide and sulfonylurea wherein the dosage form provides extended-release of biguanide as well as of sulfonylurea. Particularly the invntion relates to a layered tablet for the combination of highly water-soluble, high dose metformin and ...

The present invention relates to stable sustained release oral dosage forms of gabapentin and process for the preparation thereof wherein the dosage form provides substantially constant plasma levels of gabapentin up to 24 hours.

The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present inve...

This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclo...

1. A process for the preparation of phenyloxazolidinone derivative of Formula XII as shown in Scheme IIIB of the accompanied drawings and its pharmaceutically acceptable salts, enantiomers, diastereomers, N-oxides, prodrugs or metabolites, wherein which method comprises reacting a compound of Formula IX with hydrox...

A compound having the structure of Formula I, and its pharmaceutically acceptable salts, polymorphs, pharmaceutically acceptable solvates, enantiomers, diastereomers, N-oxides, prodrugs, or metabolites, wherein X is selected from the group consisting of CH2, CO, CS, and S02; Ar is a substituted phenyl group havin...

The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharma-ceutical compositions containing the compounds of the present invention as anti-mi-crobials. The compounds are useful antimicrobial agents, effective agains...

The invention relates to an amorphous form of Cefditoren pivoxil, which has improved solubility; adn a process for the preparation of amorphous Cefditoren pivoxil.

The invention relates to particular hydroxyl and protected hydroxyl derivatives of compounds known to be useful as HMG CoA-reductase inhibitors. In particular, herein are provided hydroxyl and protected hydroxyl compounds of Formula I and their corresponding lactones.

This invention relates to use of a compound of Formula I, in the manufacture of pharmaceutical compositions for treating or preventing disuse or disorder mediated through and/or α idadrenergic receptors, paScularly benign prostatic hyperplasia (BPH) or lower urinary tract symptoms associated with or without BPH. T...

The present invention relates to a process for preparing controlled release metformin tablets formulated as a monolithic matrix comprising metformin, hydrophilic polymers and other pharmaceutically acceptable excipients, wherein the hydrophilic polymers comprise anionic and non-ionic polymers in ratios of about 1:5 ...

The present invention relates to a controlled-release oral pharmaceutical composition in unit dosage form for administration of carbamazepine comprising: (i) a controlled-release unit comprising a coating of controlled-release polymer over immediate release core of carbamazepine and (ii) an ente...

The technical field of the invention relates to stable solid dosage forms of amlodipine besylate and benazepril hydrochloride; and processes for their preparation.

The invention relates to solvates of cefprozil. The invention also relates to processes for preparing the solvates of cefprozil, crystalline cefprozil from said solvates and pharmaceutical compositions that include the crystalline cefprozil.

The present invention relates to a process for the preparation of solid dosage forms of amorphous Valganciclovir hydrochloride by dry method.

The present invention relates to a process for the preparation of citalopram hydrobromide.

The present invention relates to a process for the preparation of pure Pravastatin sodium.

A Process for the production of amorphous atorvastatin calcium and stabilized, amorphous atorvastatin calcium is provided.

The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rh...

The technical field of the present invention relates to the selection of lubricants to provide a storage stable tablet of fosinopril, alone or in combination with a diuretic, as well as processes of preparation of the stable tablets. In particular, the lubricants are a combination of colloidal silicon dioxide and ta...

The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, a water-swellable polymer, and an alginic acid derivative to cause the release rate of the active ingredient of the tablets to be independent of pH and gastric residence time. ...

The present invention relates to certain heterocylic derivatives, in particular isoxazoline and isothiazoline derivatives as cell adhesion inhibitors. The compounds of this invention can be useful, for inhibition and prevention of cell adhesion and cell adhesion mediated pathologies including inflammatory and autoim...

The present invention relates to a novel amorphous form of tiagabine hydrochloride, an N-(butenysubstituted)-azaheheterocyclic carboxylic acid, process for preparing the amorphous form, pharmaceutical compositions comprising the amorphous form, and its use as a selective GABA'ergic activity enhancer for the treatmen...

The present invention relates to rapidly disintegrating pharmaceutical compositions of Nateglinide.

A process for the purification of voglibose is provided. Also processes for the purification of substituted or unsubstituted 5-oxo-1,2,3,4-cyclohexanetetrol, and subtituted 5-amino-1,2,3,4-cyclohexanetetrol, which are useful intermediates in the preparation of voglibose are provided.

The invention relates to taste masked dosage forms utilizing low amounts of taste masking polymer, and simple and economical processes for the preparation of the taste masked dosage forms. The taste-masked dosage forms. The taste-masked dosage form includes one or more drugs and one or more cationic polymers synthes...

The present invention relates to extended release tablet containing metformin and glipizide for treating patients with non-insulin dependent diabetes mellitus (NIDDM) on a once-a day basis. The extended release tablet provides therapeutically effective plasma levels of metformin as well as glipizide for a period of ...

The present invention relates to the metabolites of 2-{3-[4-(2-isopoxyphenyl) piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-1h-isoindole-1,3(2H)-dione of formula 1. The disclosed compounds can function as alpha1a-adrenoceptor antagonists and thus can be used for the treatment of benign prostatic hyperplasia (BPH) an...

The present invention is directed to a process for preparation of (S)-2-aminobutanamide of Formula1. In addition, the present invention also provides a process for preparation of levetiracetam of Formula II.

The present invention provides substantially amorphous fluvastatin sodium, anhydrous crystalline fluvastatin sodium and a novel polymorphic form of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof for antagonizing HMG-CoA. The novel polymorphic form is designated as Form R-16 of ...

A process for preparing (S)-tetrahydro-alfa-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic acid, an intermediate that is useful in the synthesis of HIV protease inhibitors is described. The process under consideration comprises the following steps: - L-valine is reacted with acrylonitrile and alkyl chloroformate; the ...

The present invention relates to novel polymorphic form of efavirenz. The novel polymorphic form is designated as Form & of efavirenz.

The present invention relates to processes for the preparation of crystalline polymorphic forms of cefdinir.

An improved process for preparation of 2-amino-5-protected-amino-3-hydroxy-1,6-diphenylhexana or an acid addition salt thereof which is a useful intermediate for preparing compounds with antiviral activity.

The present invention provides stable polymorphic Form 1 of donepezil hydrochloride, process for its preparation and pharmaceutical compositions and method of treating Alzheimer's disease thereof.

The present invention relates to a novel acid addition salt of 2-isopropyl-4-(((N-methyl)amino)methyl)thiazole of Formula I which is a useful intermediate for preparing HIV protease inhibitors. The present invention further provides a process for preparation of ritonavir, which is a HIV protease inhibitor using the ...

The present invention relates to a method for clarifying, screening, sifting, separating, and sorting substances of pharmaceutical interest using an ultrasonic vibrosifter technology. The present invention provides an excellent process which comprises of applying an ultrasonic frequency to a mechanical sieve for...

It relates stabilized statin particles comprising amorphous statin and stabilizers, wherein the statin is coated with stabilizers and process for preparation thereof. It further relates to pharmaceutical composition comprising stabilized statin particles and process for preparation thereof.

NA

The present invention relates to a process for the preparation of eszopiclone.

Stable ointment comprising medicament, carboxyvinyl polymer, non aqueous-water miscible solvent base and/or oleagineous base, and the process of preparation thereof are disclosed.

The technical field of the present invention relates to capsule dosage forms comprising valsartan and hydrochlorothiazide (HCTZ); and process of preparation thereof.

The present invention relates to novel crystalline form R of atorvastatin hemi calcium salt and hydrates thereof useful as pharmaceutical agents, to methods for their production and isolation, to pharmaceutical compositions which include novel crystalline form R of atorvastatin hemi calcium salt and hydrates thereof...

Amorphous atorvastatin calcium essentially fre of the impurities and residual solvents, it's pharmaceutical composition and method of treating hypercholesterolemia and hyperlipidemia comprising administering a therapeutically effective amount of amorphous atorvastatin calcium is provided.

The present invention relates to azole derivatives of Formula I, as potential antifungal agents.This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and / or preventing the fungal infections in mammals, preferably humans. This inve...

A process of improving the aqueous solubility of sulfonylurea by co-pulverizing a mixture of sulfonylurea and cyclodextrin.

The present invention provides substituted oxazolidinone derivatives, which can be used as antimicrobial agents. Compounds disclosed can be used for the treatment or prevention of a condition caused by or contributed to by bacteria, such as, inter alia, multiply-resistant Staphylococci, Streptococci, Enterococci, Ba...

The present invention relates to a monocompartment osmotic controlled delivery system of glipizide, providing a biphasic release of glipizide. The biphasic release may be achieved with the use of atleast one alkali metal or alkali earth metal derivative in the core composition.

The present invention provides a process for the preparation of clopidogrel and its pharmaceutically acceptable salts thereof comprises the resolving racemic methyl alpha-5- (4,5,6,7-tetrahydro[3,2-c]thienopyridyl)(2-chlorophenyl)-acetate by the salt formation of methyl alpha-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridy...

The present invention relates to novel polymorphic forms of efavirenz. The novel polymorphic forms are designated as Form N, Form O and Form P of efavirenz.

The present invention relates to a tablet comprising sertraline or pharmaceutically acceptable salts thereof having a particle size wherein d90 < 350 um, a diluent, a binder, a disintegrant and a lubricant or a glidants; and process for preparation thereof.

The present invention provides a process for the preparation of 5-amino-2-benzofuran-1(3H)-one of Formula1, which is a useful intermediate in the preparation of citalopram. The present invention further provides a process for preparation of citalopram or salts thereof.

A topical composition of terbinafine comprising terbinafine, non-ionic surfactant, and fatty acid and/or alcohol; and process of preparation thereof is disclosed.

The present invention relates to a dry process for the preparation of amorphous Cefditoren pivoxil solid dosage forms wherein the process comprises mixing amorphous Cefditoren pivoxil optionally with a surfactant, and one or more pharmaceutically acceptable excipient(s) and forming into a solid dosage form. ...

The present invention relates to processes for the preparation of zolpidem of Formula V as shown in the accompanying drawings or pharmaceutically acceptable salts thereof from N, N-dimethyl-3-(4-methyl) benzoyl propionamide of Formula II. The process includes (a) reacting N,N-dimethyl-3-(4-methyl) benzoyl propionami...

The present invention provides α1a and/or α1d adrenergic receptor antagonists, which can be used for treatment of benign prostatic hyperplasia (BPH) or related symptoms thereof or lower urinary tract symptoms (LUTS) with or without BPH. and process for the synthesis of these compounds. Pharmaceutically acceptable sa...

NOT AVAILABLE

The present invention relates to rapidly disintegrating solid dosage forms of risperidone for oral administration prepared by conventional tabletting procedures.

The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a...

This present invention generally relates to muscarinic receptor antagonists of Formula (1), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepr...

The invention relates to a stabilized delayed release pharmaceutical composition of Rabeprazole comprising: a) tablet core comprising Rabeprazole or pharmaceutically acceptable thereof, sodium carbonate and crospovidone; b) seal coating comprising ethyl cellulose and crospovidone and c) an enteric coating. ...

The present invention relates to a pharmaceutical composition comprising montelukast sodium and levocetirizine dihydrochloride in a single dosage form wherein there is minimum interaction between both the drugs.

The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, athe...

The present invention relates to pharmaceutical compositions of nateglinide with 50-70% of water-soluble filler alone or in combination with a channeling agent.

The invention relates to processes for the preparation of pure levetiracetam. The invention also relates to pharmaceutical compositions that include the pure levetiracetam.

The field of the invention relates to pharmaceutical compositions of moxifloxacin. The invention also relates to processes for the preparation of such compositions.

The technical field of the invention relates to solid pharmaceutical compositions of clarithromycin with enhanced absorption and dissolution characteristics provided by micronizing the clarithromycin and one or more wetting agents.

The present invention relates to the preparation of a nanoparticulate isotretinoin composition having enhanced bioavailability.

The present invention relates to a novel crystalline cefdinir potassium dihydrate, to a process for its preparation and to a method of preparing pure cefdinir via the crystalline salt.

The present invention relates to a stabilized dosage form comprising (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid or pharmaceutically acceptable salts thereof as active ingredient, wherein the aqueous dispersion or solution ...

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided.

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV. ...

The present invention relates to a process for preparation of crystalline Form I of clopidogrel hydrochloride comprising dissolving clopidogrel free base in one or more solvents selected from 1,2-dimethoxyethane, dimethoxy methane, methoxy ethoxyethane, methoxy propoxymethane or mixtures thereof, adding hydrogen chl...

Provided are novel pyrido-pyrimidine derivatives, which can be used as anti-inflammatory agents. Also provided are pharmaceutical compositions comprising one or more pyrido-pyrimidine derivatives, as well as methods of treating autoimmune diseases, inflammation or associated pathologies, including for example, sepsi...

The present invention provides a process for the preparation of crystalline lyophilized sodium bicarbonate.

The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CNS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic r...

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. P...

The present invention provides a simple process for preparation of highly pure pioglitazone or salt thereof. In addition the present invention provides pioglitazone or salt thereof having 0.1% or less of dehydropioglitazone impurity.

The present invention relates to a novel polymorphic form I of the antimalarial agent Lumefantrine. The invention further relates to highly pure lemfantrine and process for preparation thereof.

The present invention relates to α1a and/or α1d adrenergic receptor antagonists, which can be used for safe and effective treatment of a disease or disorder mediated through α1a and/or α1d adrenergic receptors. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the rel...

The present invention provides a one-pot process for preparation of nelfinavir or salts thereof. The present invention further provides novel crystalline Form I of Nelfinavir mesylate and process for its preparation.

Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal orga...

The present invention relates to a novel formate salt of gemifloxacin, process for its preparation, pharmaceutical compositions comprising it and method of treatment comprising administration of formate salt of gemifloxacin or its hydrate.

The present invention relates to a process for the preparation of crystalline Form I of Dolasetron mesylate monohydrate.

The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against bacterium such as Staphyloc...

The present invention relates to a stable dosage form of Nateglinide with enhanced dissolution profile and a process of preparation thereof.

The present invention relates to stable sustained release oral dosage forms of gabapentin and processes for their preparation. The sustained release tablet includes an intragranular portion and an extragranular portion. The intragranular portion includes gabapentin and the extragranular portion includes one or more ...

The present invention relates to solid oral dosage forms of gatifloxacin having reproducible release characteristics and processes for their preparation. The solid oral dosage form includes an intragranular phase and an extragranular phase. The intragranular phase includes gatifloxacin and one or more of a filler, a...

The invention relates to cilostazol adsorbates, and processes for their preparation. It also relates to oral phan icaal compositions that include the cilostazol adsorbate.

The technical field of the invention relates to pharmaceutical compositions for delivering drugs in the colon using an interpolymer complexation of a cationic polymeric glucosamine or its derivatives and an anionic, cross-linked, polyacrylic acid or its derivatives. The colon-specific drug delivery system includes (...

The present invention relates to a novel way of packing a gas eluting dry powder product in a pressure nil bag system comprising an inner bag twist tied with a cable tie and an outer bag accommodating a recloseable membrane based valve.

The present invention relates to a new and industrially advantageous process for the preparation of (lα, 5α, 6α)-6-aminomethyl-3-benzyl-3-azabicyclo[3.1.0]hexane, a key intermediate lor the synthesis of azabicyclo quinolone derivatives as antimicrobials and for the synthesis of various azabicyclo[3.1.0]hexane deriva...

The technical field of the present invention relates to stable pharmaceutical compositions of acid-labile benzimidazole derivative using increased amounts of low-viscosity hydroxypropylcellulose, and processes for the preparation of these compositions. The pharmaceutical composition includes one or more cores. The c...

The present invention relates to topical pharmaceutical formulation of acyclovir suitable for the treatment of viral infections of skin and mucosa.

This invention relates to an ultraviolet spectroscopy method for the determination of sevelamer through a phosphate binding assay wherein the method involves the step of derivatisation using ammonium molybdate reagent.

Stable antimalarial oral solid dosage forms comprising Spiro or dispiro 1,2,4-trioxalones; and process of preparation thereof is disclosed. The water content of the dosage form is not more than 6.5 % w/w.

The invention relates to processes for the preparation of pure voglibose. The invention also relates to the preparation of acid addition salts of voglibose. More particularly, it relates to the preparation of crystalline hydrochloride salt of voglibose. The invention also relates to pharmaceutical compositions that ...

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes,...

A compound having the structure of Formula I, as shown in the accompanied drawings, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, stereoisomers, N-oxides, polymorphs, prodrugs, or metabolites.

The present invention relates to certain non peptidyl derivatives as very late antigen (VLA-4)inhibitors and to the processes for the synthesis of the same. The compounds of this invention can be useful, for inhibition and prevention of cell adhesion and cell adhesion mediated pathologies including inflammatory adn...

The present invention relates to a novel acid addition salt of narwedine propylene glycol ketal of Formula I which is a useful intermediate in synthesis of narwedine and .

A solid pharmaceutical dosage form for oral administration, the dosage form comprising: an extended release layer comprising a biguanide; and an immediate release layer comprising a sulfonylurea.

The present invention relates to wet granulated controlled release compositions comprising aceclofenac or a pharmaceutically acceptable salt thereof and one or more hydrophilic polymers.

The present invention relates to a highly pure (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholin-2-yl 3,5-bis(trifluoromethyl)benzoate of Formula II, and a process for its preparation. The present invention further provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof, ...

The present invention relates to a novel crystalline form of Lamivudine. The novel crystalline form of the present invention is designated as Form IV. The present invention further relates to a process for the preparation of crystalline Form IV of lamivudine.

The present invention relates to stable From I of ritonavir and a process for preparation of Form I of Ritonavir.

The present invention relates to a multiple-unit modified release carbamazepine composition for oral administration comprising; (i) at least one extended release unit, and (ii) at least one enteric release unit.

The present invention provides salts of Quetiapine and processes for their preparation. The present invnetion further relates to polymorphic forms of salts of quetiapine, processes for their preparation and pharmaceutical compositions thereof.

The present invention relates to multilayered modified release formulation comprising amoxicillin and clavulanate, process of preparation thereof and method of treating bacterial infection using these formulations. The multiiayered modified release formulation comprises: - an immediate release layer comprising amox...

The present invention relates to a process for the preparation of lansoprazole with desired particle-size in high yield and purity with appropriate particle-size distribution.

The present invention relates to cilostazol composition wherein 90% of cilostazol particles have a particle size less than about 50 µm, and to a process for preparing it.

The present invention provides ketolide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against bacterium, for example, St...

Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds described herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal orga...

The present invention relates to certain substituted phenyl oxazohdinones and to processes for the synthesis of the same.

NA

The present invention relates to pharmaceutical compositions of didanosine comprising a core, a sub coat comprising polyvinyl alcohol and an enteric coating. The compositions have acceptable acid resistance and release profile.

The present invention provides acylide derivatives, which can be used as antibacterial agents. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and method of treating bacterial infections.

This invention relates to certain novel α,ω-dicarboximide derivatives which selectively inhibit binding to the α1A adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of b...

The present invention relates to derivatives of 2,2,4-trisubstituted tetrahydrofuran as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably hu...

The present invention provides substituted oxazohdinone derivatives, which can be used as antimicrobial agents Compounds disclosed can be used for the treatment or prevention of a condition caused by or contributed to by bacterium such as multiply-resistant Staphylococci, Streptococci, Enterococci, Bactericides spp...

This invention relates to certain novel carboximide derivatives which selectively inhibit binding to the αIA adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of benign ...

The present invention relates to an orally administered pharmaceutical composition that is a triple combination of antidiabetic agents in which one of the antidiabetic agents is present in an extended release form and the other antidiabetic agents are present in an immediate release form.

Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV ("PDE-IV"), and atleast one other active ingredients selected from muscarinic receptor antagonists (MRA), p2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutica...

The present invention relates to a blister pack with notches for easy retrieval of fragile dosage forms.

NA

The present invention provides ketolide derivatives in the macrolide family, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against b...

The present invention relates to azole derivatives as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans

The present invention relates to disintegrant free oral compositions comprising celecoxib. It further relates to processes for preparing such compositions. It also relates to method of treating cyclooxygenase-2 mediated disorders using compositions of the present invention.

The present invention relates to novel polymorphic form of efavirenz. The novel polymorphic form is designated as Form a of efavirenz.

The present invention relates to novel polymorphic form of efavirenz. The novel polymorphic form is designated as Form y of efavirenz.

CASPASE INHIBITORS

The present invention provides a process for the preparation of crystalline imipenem by reverse osmosis.

The present invention  provides a process for the preparation of amorphous Doripenem.

The present invention provides a process for preparation of amorphous fluvastatin sodium which comprises of removing solvent from the solution of fluvastatin sodium.

Apolymorph 'Form A' of(S)-N-[[3-fluoro-4-[N-l-[4-{2-furyl-(5-nitro)methyl}]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide hydrochloride having the following 10 most intense X-ray powder diffraction peaks: (20): 26.62,26.20,24.72,21.94,21.18,20.60, 17.62, 16.84, 16.22, 14.74.

The  present  invention  relates  to  certain  substituted  phenyl oxazolidinones and to processes for the synthesis of the same.

The present invention relates to a process for the preparation of threo-3,4-epoxy-2-amino-1-substituted butane derivatives represented by general Formula I Formula-I which comprises reacting compound of Formula III or salt thereof with an active ester of acid of Formula IV and treating the product thereof with b...

Pharmaceutical dosage from of pseudoephedrine and loratadine for twice-a-day administration comprising an extended release core of pseudoephedrine and immediate release coating layer of loratadine and pseudoephedrine is disclosed. It also discloses dosage forms providing an in vitro release profile of pseudoephedrin...

The present invention relates to thiazolidinedione derivatives, which can function as alpha 1a and/or alpha 1b adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through alpha 1a and alpha 1b adrenergic receptor. Compounds disclosed herein can be used for the treatment...

The present invention relates to a stable oral pharmaceutical composition comprising irbesartan and hydrochlorothiazide, wherein the two actives are present as distinct portions within the composition

The present invention relates to a stable pharmaceutical composition of tiagabine, stabilized with a combination of BHT, BHA and EDTA,as antioxidants; process of preparing pharmaceutical compositions is also disclosed.

The technical field of the invention relates to ibuprofen-containing soft gelatin capsules, pharmaceutical compositions of a substantially clear ibuprofen solution, and process for their manufacture.

The invention relates to a new microorganism Streptomyces glaucescens MTCC 5115 and a process for producing the immunosuppressant agent, tacrolimus (FK-506) utilizing the new microorganism Streptomyces glaucescens MTCC 5115. The invention also relates to pharmaceutical compositions that include the tacrolimus (FK-50...

A solid oral dosage form of simvastatin comprising simvastatin and lactose of average particle size of about 20µm and processes of preparation thereof is disclosed.

The present invention relates to a pharmaceutical composition containing fixed dose combination of alfuzosin with solifenacin and process for the preparation thereof. The composition provides extended release of alfuzosin and immediate release of solifenacin.

The present invention relates to a simple process for the recovery of dihydroartemesinin, a useful intermediate for the preparation of ether derivatives of dihydroartemisinin which are well-known anttmalarial agents.

The present invention relates to standardized extracts of Cinnamomum cassia, wherein the extracts have antidiabetic activity. The present invention also includes the bioassay guided fractionation of the plant material leading to the identification of bioactive chemical constituents, processes for the preparation of ...

This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of discl...

This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0] hexanes. The compounds of this invention can function as muscarinic receptor antagonists, inter alia for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic re...

Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal orga...

The present invention relates to a controlled release metaxalone compositions for oral administration, as well as methods of preparing them.

The present invention relates to a dual purpose dosing device for measuring water for reconstitution of a product and the dose of the reconstituted product.

This invention generally relates to the derivatives of 1 -substituted-3 -pyrrolidines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems m...

This invention generally relates to the derivatives of 3,6-disubstituted azabicyclo [3.1.0] hexanes of the following formula [IA]. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal sy...